Current status of the management of symptomatic intracranial atherosclerotic disease: the rationale for a randomized trial of medical therapy and intracranial stenting
- 1Department of Neurosurgery, Stony Brook University Medical Center, Stony Brook, New York, New York, USA
- 2Division of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA
- 3Division of Radiology, Neurology and Neurosurgery, Washington University, St. Louis, Missouri, USA
- Correspondence to
David Fiorella, Cerebrovascular Center, Department of Neurosurgery, Stony Brook University Medical Center, HSC T-12080, Stony Brook, NY 11794-8122, USA; dfiorella{at}notes.cc.sunysb.edu
- Received 1 April 2009
- Accepted 3 April 2009
- Published Online First 3 July 2009
Abstract
Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) is a randomized trial comparing aggressive medical management alone with aggressive medical management in combination with angioplasty and stenting using the Gateway–Wingspan system in patients with symptomatic, high-grade, intracranial stenosis. This trial represents a landmark in the maturation of the field of neurointervention, establishing a foundation for evidenced-based practice. We review the natural history of symptomatic intracranial stenosis when treated medically, the available interventional therapies and the rationale for the design of the SAMMPRIS trial.
Keywords:
Notes
-
Competing interests All of the authors have NIH funding for the SAMMPRIS trial.
- © 2009, Society of NeuroInterventional Surgery.
